ADVERTISEMENT
Individualization of Therapies for Patients With HR-Positive, HER2-Negative Breast Cancer
Rick Baehner, MD, Unviersity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, discussed results from the phase 3 ADAPTcycle trial which used age, recurrence, score (as determined by Oncotype DX), biological markers, and ovarian function suppression to analyze response to short preoperative endocrine therapy in patients with HR-positive, HER2-negative breast cancer.
These results were first presented at the 2023 San Antonio Breast Cancer Symposium.
Source:
Gluz O, Christgen M, Nitz U, et al. Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334). Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract LBO1-05